A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2006
12/21/2006	WO2006135362A1 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
12/21/2006	WO2006135279A1 Method for producing alginic acid conjugats
12/21/2006	WO2006135233A1 Dendrimers multivalently substituted with active groups
12/21/2006	WO2006135176A1 Human granulocyte-colony stimulating factor isoforms
12/21/2006	WO2006134970A1 Coenzyme q10-containing water-soluble composition and process for production thereof
12/21/2006	WO2006134937A1 Skin preparation for external use
12/21/2006	WO2006134877A1 Injection
12/21/2006	WO2006134864A1 Solubilization preparation
12/21/2006	WO2006134611A1 Compositions of antiulcerative substituted benzimidazoles
12/21/2006	WO2006134406A1 Stable pharmaceutical gel of diclofenac sodium
12/21/2006	WO2006134279A2 Method for solubilizing metronidazole
12/21/2006	WO2006134272A1 Pharmaceutical composition comprising an organopolysiloxane elastomer and a solubilized active principle
12/21/2006	WO2006134166A2 Pharmaceutical active ingredient for penetrating the blood-brain barrier combined with an active ingredient obtained from biogenic poisons to combat brain tumours
12/21/2006	WO2006134148A2 Transglutaminase mediated conjugation of growth hormone
12/21/2006	WO2006133519A1 Particles comprising a releasable dopant therein
12/21/2006	WO2006133518A1 Particles having hydrophobic material therein
12/21/2006	WO2006133506A1 A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
12/21/2006	WO2006097793A3 Compositions capable of facilitating penetration across a biological barrier
12/21/2006	WO2006096461A3 Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
12/21/2006	WO2006089656A3 Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
12/21/2006	WO2006084902A8 Method of purifying a surfactant by ultrafiltration
12/21/2006	WO2006079019A3 Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
12/21/2006	WO2006050420A3 Chimeric immunogens that comprise ovalbumin
12/21/2006	WO2006014979A3 Palm fiber-based dietary supplements
12/21/2006	WO2006005058A3 Polymer-factor ix moiety conjugates
12/21/2006	WO2005118009A3 Transdermal delivery system for treatment of cognitive disorders
12/21/2006	WO2005105037A8 Use of a viscoelastic composition for treating increased intraocular pressure
12/21/2006	WO2005096789A3 Methods and compositions for imaging and biomedical applications
12/21/2006	WO2004041172A3 Interferon antagonists useful for the treatment of interferon related diseases
12/21/2006	US20060288434 Inhibiting angiogenesis in a mammal by administering an antibody which specifically binds to EphriniB2 or EphB4; cardiovascular disorders
12/21/2006	US20060287542 Non-ionic surfactants for solubilizing poorly solubule molecules
12/21/2006	US20060287266 Synthesizing a double stranded nucleic acid molecule used for treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability
12/21/2006	US20060287256 Novel nutraceutical compositions and use thereof
12/21/2006	US20060287225 injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid
12/21/2006	US20060287223 Remodeling and glycoconjugation of peptides
12/21/2006	US20060287220 Water soluble paclitaxel prodrugs
12/21/2006	US20060286603 Combinatorial libraries of monomer domains
12/21/2006	US20060286205 Biomass hydrolysate and uses and production thereof
12/21/2006	US20060286175 Surfactant- and detergent-free with a continuous liquid phase containing the nanoparticles and a dispersed phase containing one or more medicament particles; phases do not separate due to flocculation or agglomeration
12/21/2006	US20060286174 non-coated complex particulate comprising ion consisting of a styrene-divinylbenzene sulfonic acid cationic exchange resin and a pharmaceutically active material such as oxycodone hydrochloride, tramadol hydrochloride complexed with ion exchange resin; avoids use of coatings and large amounts of solvents
12/21/2006	US20060286164 Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
12/21/2006	US20060286163 Pharmaceutical composition of topiramate
12/21/2006	US20060286157 Protein mixtures for wound healing
12/21/2006	US20060286150 Prevent menopause syndrome; therapy for skin aging; topical applying
12/21/2006	US20060286149 Low molecular weight polyglucosamines and polygalactosamines
12/21/2006	US20060286130 Sterile gelling agents
12/21/2006	US20060286126 preparing closed bacterial ghosts by specific interactions between partners of a bioaffinity binding pair; operate with a higher degree of efficiency
12/21/2006	US20060286113 single domain antibody AFAI; binds to non-small cell lung carcinoma; kits
12/21/2006	US20060286099 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/21/2006	US20060286098 Derived from cocaine linked to cholera B toxin; antibodies; for treatment of cocaine addiction; immunization
12/21/2006	US20060286097 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/21/2006	US20060286096 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/21/2006	US20060286095 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/21/2006	US20060286094 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/21/2006	US20060286087 Recombinant alpha-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
12/21/2006	US20060286086 Lysozyme-based food stuff
12/21/2006	US20060286069 G-CSF Conjugates
12/21/2006	US20060286068 Polypeptides exhibiting granulocyte colony-stimulating factor (G-CSF) activity; conjugates between the polypeptides and a non-polypeptide moiety (PEG); for treatment of neutropenia or leukopenia; low in vitro bioactivity, long in vivo half-life, reduced receptor-mediated clearance
12/21/2006	US20060286065 Useful in extending the in vivo circulating life of biologically active materials; bicine linker allows for the manipulation of the hydrolysis rate of the prodrug, thereby releasing the native entities at various rates in vivo as well as in vitro
12/21/2006	US20060286043 Delivery of antihistamines through an inhalation route
12/21/2006	US20060286042 Condensation aerosol for delivery of a drug selected from the group consisting of zaleplon, zolpidem and zopiclone
12/21/2006	DE19854497B4 Fließfähige Zubereitungen vom Emulsionstyp W/O mit erhöhtem Wassergehalt Flowable preparations emulsion type W / O with increased water content
12/21/2006	CA2612794A1 Transglutaminase mediated conjugation of growth hormone
12/21/2006	CA2612175A1 Particles having hydrophobic material therein
12/21/2006	CA2611917A1 Injection
12/21/2006	CA2611883A1 Method for solubilizing metronidazole
12/21/2006	CA2611869A1 Pharmaceutical composition comprising an organopolysiloxane elastomer and a solubilized active principle
12/21/2006	CA2611836A1 Transmucosal delivery of peptide derivatives
12/21/2006	CA2611831A1 A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
12/21/2006	CA2611190A1 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
12/20/2006	EP1734122A2 APO-2 ligand
12/20/2006	EP1734037A2 Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol"
12/20/2006	EP1733742A1 Dendrimers multivalently substituted with active groups
12/20/2006	EP1733741A2 O/W-emulsions comprising one or several bioquinones and an elevated amount of glycerine
12/20/2006	EP1733736A2 Method of producing recombinant antibodies against tumours
12/20/2006	EP1733725A1 Farmaceutical formulations comprising at least one HIV protease inhibiting compound
12/20/2006	EP1733720A1 Composition comprising reduced-form coenzyme q10 and carotenoid compound
12/20/2006	EP1733719A1 Percutaneous absorption-type pharmaceutical preparation using a metal chloride, preferably sodium chloride, for preventing cohesive failure
12/20/2006	EP1733397A2 Anti-infectious hydrogel compositions
12/20/2006	EP1733237A2 Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara)
12/20/2006	EP1732953A2 Hydroxyethyl starch
12/20/2006	EP1732613A2 Use of serum albumin binding peptides conjugates for the preparation of a medicament
12/20/2006	EP1732612A1 Tripartite conjugates containing a structure interacting with cell membrane rafts and their use
12/20/2006	EP1732611A1 Production and use of the methotrexate-albumin conjugate as an immunosuppressive agent in gvhd
12/20/2006	EP1732610A2 Targeted serotonin reuptake inhibitors
12/20/2006	EP1732609A2 Conjugates of hydroxyalkyl starch and a protein
12/20/2006	EP1732608A2 Folate conjugates and complexes
12/20/2006	EP1732607A2 Polymeric prodrug with a self-immolative linker
12/20/2006	EP1732606A2 Formulations decreasing infectivity of pulmonary diseases
12/20/2006	EP1732605A2 Multi-vitamin and mineral nutritional supplements
12/20/2006	EP1732603A1 Cytotoxicity mediation of cells evidencing surface expression of cd63
12/20/2006	EP1732602A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp
12/20/2006	EP1732601A1 Cytotoxicity mediation of cells evidencing surface expression of cd44
12/20/2006	EP1732600A2 Uses of anti-ctla-4 antibodies
12/20/2006	EP1732584A2 Multi-component biological transport systems
12/20/2006	EP1732576A1 Method for the photostabilisation of phycobiliproteins in an aqueous extract, compositions containing stabilised phycobiliproteins and use of stabilised phycobiliproteins
12/20/2006	EP1732535A1 Injectable composition for the treatment of cancers
12/20/2006	EP1732529A1 Gossypol co-crystals and the use thereof
12/20/2006	EP1732524A2 Methods and compositions for treatment of ion imbalances
12/20/2006	EP1732523A1 Ion binding polymers and uses thereof

1 ... 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 ... 1712